TP53 and breast carcinoma: Additional screens with both Pten∆f:p53∆f and Pten∆f:p53R270H tumors as well as with human Pten/p53-deficient breast cancer lines using large libraries of divergent compounds may uncover new potent drugs for this aggressive cancer subtype.